{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007831","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.652173+00:00","generated_at":"2026-05-16T00:53:55.354346+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status","bullets":["Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.","FDA Fast Track designation provides clear regulatory pathway for ateganosine.","First and only direct telomere-targeting anticancer agent in clinical development.","Targets ~50,000 US patients annually in 3L NSCLC with no established standard of care.","CEO Vlad Vitoc cites $50 billion global immunotherapy market opportunity in letter."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007831","json":"https://secwatch.observer/filing/0001493152-26-007831.json","markdown":"https://secwatch.observer/filing/0001493152-26-007831.md","text":"https://secwatch.observer/filing/0001493152-26-007831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226007831/0001493152-26-007831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226007831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:53:55.354346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}